Developing novel health technology requires navigating complex FDA regulatory pathways. Ensuring early dialogue with regulatory specialists prevents costly timeline delays and ensures compliance with institutional review boards (IRBs).

Key Milestones for Device Translation

From pre-investigational submissions (Pre-Subs) to pivotal clinical trials, rigorous documentation of safety endpoints is paramount.